当前位置: X-MOL首页全球导师 国内导师 › 应天雷

个人简介

教育经历 2001.09—2005.09 复旦大学化学专业本科生 2005.09—2010.07 复旦大学无机化学专业博士研究生 工作经历 2010.07—2014.10 美国国立卫生研究院博士后研究员 2014.10—至今 复旦大学基础医学院研究员(其间, 2021.01—至今 上海合成免疫工程技术研究中心主任) 获得奖项 2021,上海市青年五四奖章,共青团上海市委 2020,上海市科技进步一等奖,上海市人民政府 2020,上海青年科技英才,上海市科协、上海科技发展基金会 2020,第三届转化医学创新奖,上海广慈转化医学研究发展基金会 2019,复旦大学青年五四奖章,共青团复旦大学委员会 2015,“大挑战2015”青年科学家奖,科技部、比尔及梅琳达盖茨基金会 2014,美国联邦技术转让奖,美国国家癌症研究所 2012,美国联邦技术转让奖,美国国家癌症研究所

研究领域

生物医药领域,恶性肿瘤及流感、新型冠状病毒等重大疾病的治疗性全人源单抗药物研发 合成免疫学,创新免疫治疗药物及疗法研发、新技术在抗体组学研究中的应用、新结构抗体的作用机制研究

近期论文

查看导师新发文章 (温馨提示:请注意重名现象,建议点开原文通过作者单位确认)

Li, C.#, Zhan, W.#, Yang, Z.#, Tu, C.#, Hu, G.#, Zhang, X., Song, W., Du, S., Zhu, Y., Huang, K., Kong, Y., Zhang, M., Mao, Q., Gu, X., Zhang, Y., Xie, Y., Deng, Q., Song, Y., Chen, Z., Lu, L., Jiang, S., Wu, Y.*, Sun, L.*, Ying, T.* Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. Cell, 185, 1–13, 2022 Wang, C.#, Hong, J.#*, Yang, Z.#, Zhou, X., Yang, Y., Kong, Y., Chen, B., Wu, H., Qian, B. Z., Dimitrov, D. S., Zhou, X., Wu, Y.*, Ying, T.* Design of a Novel Fab-Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use. Small Methods, 6(2), e2100966, 2021 Jin, Y. J., Yu, D., Tian, X. L., Li, H. X., Zhou, X. C., Kong, Y., Zhang, W., Zhang, L., Lei, C., Yang, Z. L., Tu, C., Wu, Y. L., Ying, T.* A novel and effective approach to generate germline-like monoclonal antibodies by integration of phage and mammalian cell display platforms. Acta Pharmacol Sin. 43(4):954-962, 2021 Li, C.#, Tian, X.#, Jia, X.#, Wan, J., Lu, L., Jiang, S., Lan, F., Lu, Y.*, Wu, Y.*, Ying, T.* The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2. Signal Transduct Target Ther, 6(1), 132, 2021 Yang, Z.#*, Wang, Y.#, Jin, Y.#, Zhu, Y.#, Wu, Y.#, Li, C., Kong, Y., Song, W., Tian, X., Zhan, W., Huang, A., Zhou, S., Xia, S., Tian, X., Peng, C., Chen, C., Shi, Y., Hu, G., Du, S., Wang, Y., Xie, Y., Jiang, S., Lu, L., Sun, L., Song, Y.*, Ying, T.* A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. Signal Transduct Target Ther, 6(1), 378, 2021 Wu, Y.*, Li, C., Xia, S., Tian, X., Kong, Y., Wang, Z., Gu, C., Zhang, R., Tu, C., Xie, Y., Yang, Z., Lu, L., Jiang, S., Ying, T.* Identification of Human Single-Domain Antibodies against SARS-CoV-2. Cell Host Microbe. 27(6):891-898, 2020 Tian, X#., Li, C.#, Huang, A., Xia, S., Lu, S., Shi, Z., Lu, L., Jiang, S., Yang, Z., Wu, Y.*, Ying, T.* Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect, 9(1), 382-385, 2020 Hu D.#, Zhu Z.#, Li S.#, Deng Y.#, Wu Y., Zhang N., Puri V., Wang C., Zou P., Lei C., Tian X., Wang Y., Zhao Q., Li W., Prabakaran P., Feng Y., Cardosa J., Qin C., Zhou X.*, Dimitrov D.S.*, Ying T.* A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III. PLoS Pathog. 15(6):e1007836, 2019 Wu Y.#, Xue J.#, Wang C., Li W., Wang L., Chen W., Prabakaran P., Kong D., Jin Y., Hu D., Wang Y., Lei C., Yu D., Tu C., Bardhi A., Sidorov I., Ma L., Goldstein H., Qin C., Lu L., Jiang S., Dimitrov D.S., Ying T.* Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection. J Virol. 93(20). pii: e01077-19, 2019 Yu, F., Song, H., Wu, Y., Chang, S.Y., Wang, L., Li, W., Hong, B., Xia, S., Wang, C., Khurana, S., Feng, Y., Wang, Y., Sun, Z., He, B., Hou, D., Manischewitz, J., King, L.R., Song, Y., Min, J.Y., Golding, H., Ji, X., Lu, L., Jiang, S., Dimitrov, D.S., Ying, T.* A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. Cell Host Microbe. 22:1-13, 2017.

学术兼职

2020-今 中国生物工程学会抗体工程分会 副主任委员 2020-今 中国老年保健医学研究会肿瘤防治分会 副主任委员 2021-今 中国老年学和老年医学学会转化医学分会 副主任委员 2021-今 中国医药生物技术协会单克隆抗体专业委员会 委员 2021-今 上海市肺部损伤与修复重点实验室 副主任

推荐链接
down
wechat
bug